Tirzepatide 40
Dual GIP / GLP-1 agonist in a 40 mg click pen, studied for metabolic and weight research.Each click delivers133 µgfrom a 3 mL · 300-click pen.
Featured in these stacks: Lean Stack, Metabolic Reset.
how many clicks
for your dose?
ThisTirzepatide 40pen holds40 mgacross 300 clicks, so each click delivers133 µg. Tap a dose or turn the dial; we'll count the clicks. For research reference only.
why349researchers chose this pen
chose it for the click dosing, no syringes, no unit maths.
verified purity, checked against the public COA before first use.
precise clicks in every 3 mL pen, the whole protocol in one barrel.
re-order or refer a colleague within three months.
about the
Tirzepatide 40pen
Tirzepatide is a dual GIP / GLP-1 receptor agonist, supplied in a pre-filled 3 mL / 300-click pen for metabolic research.
Certificate of analysis"Counted my clicks, done in ten seconds. No syringes, no unit maths, the dosing card lives on my desk now."
"Checked the batch number against the public COA before first use, matched to the decimal. That's why I switched."
"Arrived cold, packed like something precious. Temperature strip still green on arrival. Genuinely impressed."
why a pen beats
a vial & syringe
Traditional research peptides arrive as lyophilised powder that must be reconstituted, drawn into insulin syringes, and converted from milligrams to units by hand, every step a chance for a dosing error.
A multi-dose pen removes the whole failure chain. The peptide arrivesalready dissolved and calibrated. Attach a fresh needle, turn the dial until you count your clicks, and you're done, the same audible-click mechanism trusted in insulin and GLP-1 pens worldwide.
Pens travel and store better, too: no open vials, no bent needles, no septum contamination after repeated draws. One sealed barrel, ten sterile needles, one dosing card.
how to buy
peptides safely
The peptide market has a purity problem: independent surveys routinely find underdosed, mislabelled or contaminated product sold online. The only reliable defence isthird-party verification you can check yourself, not a supplier's own claims.
Before buying any peptide pen, ask three questions. Is every batch tested by an independent lab? Is the certificate of analysis available, so you can check your exact lot before first use? And does it ship cold-chain, insulated and gel-packed, so what was tested is what arrives?
Veyvora answers yes on every order, independent assay, a COA on request against the batch number, and cold dispatch within 24 hours, paperwork packed inside.
pairs well with
view all
Tirzepatide 40 mg Research Pen | Veyvora
Veyvora’s Tirzepatide 40 mg Research Pen is a multi-dose click pen supplied for in-vitro laboratory research use only, containing 40 mg of tirzepatide across a 3 mL barrel with 300 measured clicks, equating to approximately 133 micrograms per click (Veyvora product specification, 2026).
This page covers what the Veyvora 40 mg Research Pen contains and how its specifications compare to the only MHRA-authorised tirzepatide product in the UK; what batch documentation to request before procurement; and what UK regulatory obligations apply to institutional buyers of research-use-only peptides.
Price: Contact Veyvora directly for current GBP pricing and availability. Availability: See live stock status on the Veyvora product page. Purchase: Proceed via the Veyvora checkout for verified batch allocation.
Quick-reference specification
| Parameter | Veyvora specification (2026) |
|---|---|
| Active substance | Tirzepatide |
| Total fill | 40 mg |
| Fill volume | 3 mL |
| Delivery mechanism | Pre-filled click pen |
| Clicks per barrel | 300 |
| Approximate delivery per click | 133 µg |
| Needle gauge / length | 31G, 6 mm |
| Intended use | In-vitro laboratory research only |
Regulatory notice: In the United Kingdom, tirzepatide is a prescription-only medicine (POM) authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) as Mounjaro. A 40 mg research pen is not an MHRA-authorised presentation. Lawful supply of tirzepatide as a medicinal product requires a valid prescription and a registered pharmacy under the Human Medicines Regulations 2012 [2]. The MHRA has issued repeated warnings against purchasing injectable GLP-1 (glucagon-like peptide-1) medicines, such as tirzepatide and semaglutide, outside registered pharmacy channels [2].
Last reviewed: June 2026.
Key Takeaways
- The Veyvora 40 mg Research Pen is supplied for in-vitro laboratory research only; it is not an MHRA-authorised medicinal product and carries no licensed indication.
- Each pen ships with an independent, batch-specific certificate of analysis (COA) reporting LC-MS identity, HPLC purity (≥ 98.0%), peptide content and a safety panel; match it to the pen’s batch number before procurement.
- A “research use only” label does not exempt a product from UK medicines law; institutional buyers must confirm the legal basis for procurement with their compliance or legal team before placing an order.
- Storage conditions for the authorised product Mounjaro KwikPen (2–8 °C, protected from light) cannot be assumed to apply to an unlicensed research pen without independent stability data.
- Contact Veyvora directly for current GBP pricing, stock status and batch documentation before committing to purchase.
Product Identity and Scope
Veyvora’s Tirzepatide 40 mg Research Pen is a pre-filled multi-dose click pen containing 40 mg of tirzepatide in a 3 mL barrel, delivering approximately 133 micrograms per click across 300 measured clicks, supplied strictly for in-vitro laboratory research use only and not presented as a medicinal product for human administration (Veyvora product specification, 2026).
Tirzepatide is a synthetic dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist that binds to and activates two distinct hormone receptors involved in glucose regulation and appetite signalling. That dual mechanism separates it from single-receptor GLP-1 agonists such as semaglutide. The only MHRA-authorised tirzepatide presentation in the United Kingdom is Mounjaro, a prescription-only medicine available in dose strengths from 2.5 mg to 15 mg per injection [3]. The Veyvora 40 mg Research Pen is not an MHRA-authorised medicinal product and carries no licensed indication.
The specifications above reflect Veyvora’s published product data; confirm them against the batch-specific certificate of analysis, which ships with each pen, before procurement. Researchers should verify your batch against its COA once a batch number is allocated, and consult what HPLC purity does and does not prove before drawing conclusions from any accompanying analytical data.
Verified Specifications
The figures below reflect Veyvora’s published product data; confirm each against the batch-specific certificate of analysis (COA) for the lot supplied, which reports composition, identity and purity, before procurement.
| Parameter | Veyvora-stated value (2026) | Independent verification |
|---|---|---|
| Total tirzepatide content | 40 mg | Confirm against batch COA |
| Fill volume | 3 mL | Confirm against batch COA |
| Clicks per barrel | 300 | Confirm against batch COA |
| Delivery per click | ~133 micrograms | Confirm against batch COA |
| Excipients | Confirm with operator | Confirm against batch COA |
| Needle interface | 31G, 6 mm | Confirm with operator |
For context, the only MHRA-authorised tirzepatide pen in the United Kingdom is Mounjaro KwikPen (Eli Lilly), available in dose strengths from 2.5 mg to 15 mg per injection, with specifications set out in the UK Summary of Product Characteristics [1]. The Veyvora 40 mg Research Pen is not an authorised medicinal product, and its specifications carry no equivalent regulatory standing. That distinction matters when assessing procurement risk.
Researchers assessing receipt conditions should consult storage and stability guidance for research peptides before accepting delivery. Those who have confirmed these specifications but require a compound-level comparison may find the retatrutide versus tirzepatide comparison useful at that stage.
Batch Documentation and Analytical Evidence
Each Veyvora Tirzepatide 40 mg Research Pen ships with an independent, batch-specific certificate of analysis (COA) reporting LC-MS identity, HPLC purity (≥ 98.0%), peptide content (95–105%) and a safety panel. A COA is an analytical record, not an MHRA marketing authorisation; match the certificate to the pen’s batch number and confirm the analytical methods and acceptance criteria before use.
What a COA Can and Cannot Prove
Veyvora states that each batch is verified independently by Asterion Analytics, then again by Veyvora’s own internal testing. A COA reports those analytical results; it does not carry the standing of an MHRA or EMA (European Medicines Agency) assessment, a pharmacopoeial compendial standard, or an ICH Q1A(R2)-compliant stability dataset, where ICH Q1A(R2) refers to the International Council for Harmonisation guideline governing stability testing of new drug substances. For authorised tirzepatide products such as Mounjaro KwikPen, identity, purity and stability criteria are set out in the UK Summary of Product Characteristics and underpin the marketing authorisation [1]. No equivalent regulatory framework applies to an unlicensed research pen.
Where a batch number is provided at point of supply, researchers should verify your batch against its COA before use, and confirm directly with Veyvora which analytical methods, reference standards and acceptance criteria were applied. Excipient identity, endotoxin limits and sterility status are reported on the batch-specific COA; confirm them against the certificate for the lot supplied prior to procurement.
Handling and Storage
No Veyvora-specific dispatch temperature, excursion limit, in-use dating or stability dataset for the Tirzepatide 40 mg Research Pen was confirmed from live page content or batch documentation at the time of writing. Request these parameters directly from Veyvora before procurement.
Authorised Storage Conditions and Their Limits
For the licensed product Mounjaro KwikPen, the UK Summary of Product Characteristics requires refrigerated storage at 2–8 °C, protection from light, and defined in-use periods after first use [1]. Those conditions are specific to the authorised formulation, excipients and container-closure system assessed by the MHRA. Applying them to an unlicensed research pen without independent stability data generated under ICH Q1A(R2) or an equivalent framework is an unsupported assumption, because the excipient composition and container-closure system may differ materially.
For detailed guidance on what cold-chain receipt and 2–8 °C storage mean in a research-peptide context, see storage and stability guidance for research peptides. Confirm freezer prohibition, cold-chain packaging inspection on arrival and post-receipt handling directly with Veyvora before use.
Ordering Information
No verified GBP price, minimum order quantity, stock status, lead time or courier terms for the Tirzepatide 40 mg Research Pen were confirmed from live Veyvora page content or structured product data at the time of writing. Prospective buyers and distributors should contact Veyvora directly to obtain current figures before committing to procurement.
Regulatory Context for UK Procurement
In Great Britain, tirzepatide is a prescription-only medicine under the Human Medicines Regulations 2012, and lawful supply to patients requires a valid prescription through a GPhC (General Pharmaceutical Council)-registered pharmacy [2]. The MHRA issued repeated warnings against purchasing tirzepatide-based pens outside registered pharmacy channels, with enforcement activity continuing through 2024–2025 [2]. A research-pen SKU positioned for in-vitro laboratory use sits outside the consumer medicine supply chain, so institutional buyers should confirm the legal basis for procurement with their institution’s compliance or legal team before placing an order.
Research-Use-Only Limitations
A “research use only” (RUO) label does not place tirzepatide outside UK medicines law. Under the Human Medicines Regulations 2012, unlicensed supply, public advertisement and wholesale distribution of a medicinal substance without the correct MHRA licences remain criminal offences, regardless of how the product is labelled [2]. In-vitro laboratory use, where genuine, still requires lawful procurement and, where applicable, import notification. Human dosing is not permitted under any circumstances.
The MHRA authorises named medicinal products such as Mounjaro, not unlicensed research pens [2]. RUO wording is not a quality credential and is not evidence of GMP (Good Manufacturing Practice) compliance. Researchers should verify their batch against its COA and consult what HPLC purity does and does not prove before drawing conclusions from any supplier-issued analytical document.
Related Research and Comparison Pages
Authoritative regulatory context for tirzepatide in the United Kingdom sits with the MHRA and NHS [3]. Confirm any procurement decision for a research pen against current MHRA guidance on unlicensed medicines [2] before placing an order. Those evaluating compound selection will find that the retatrutide versus tirzepatide comparison sets out receptor-binding profile differences at the compound level without importing human-outcome claims into this product page.
Contact Veyvora’s research-peptide catalogue directly to request batch documentation and current GBP pricing before purchase.
Sources
[1] Tirzepatide (Mounjaro) clinical review, PubMed Central (PMC), https://pmc.ncbi.nlm.nih.gov/articles/PMC9268041/ [2] UK medicines regulator warns against buying weight-loss medicines without a prescription, GOV.UK, https://www.gov.uk/government/news/uk-medicines-regulator-warns-against-buying-weight-loss-medicines-without-a-prescription-this-new-year [3] Tirzepatide, NHS, https://www.nhs.uk/medicines/tirzepatide/
